Addiction & Substance AbuseTreatment in Dubai
Addiction/Substance Abuse is a chronic, relapsing brain disorder characterized by compulsive drug seeking and use despite harmful consequences. It involves dysregulation of the mesolimbic dopamine pathway, impaired prefrontal cortex function, altered...
Common Symptoms
- Compulsive urge to use substances despite knowing the harm they cause
- Tolerance requiring increased amounts to achieve the same effect
- Withdrawal symptoms when not using (anxiety, nausea, tremors, cravings)
- Loss of control over amount and frequency of use
- Continued use despite relationship, health, or legal problems
- Neglecting responsibilities and hobbies due to substance use
- Spending significant time obtaining, using, or recovering from substances
- Failed attempts to cut down or control use
What is this Condition?
Medical Definition
Addiction/Substance Abuse is a chronic, relapsing brain disorder characterized by compulsive drug seeking and use despite harmful consequences. It involves dysregulation of the mesolimbic dopamine pathway, impaired prefrontal cortex function, altered reward circuitry, and persistent changes in neurotransmitter systems including dopamine, glutamate, and GABA. Common substances include alcohol, opioids, stimulants, benzodiazepines, cannabis, and nicotine.
Healthy Baseline
A healthy reward system involves the ventral tegmental area releasing dopamine into the nucleus accumbens in response to natural rewards (food, social connection, achievement). The prefrontal cortex exercises executive control over impulsive drives, allowing for decision-making, delay of gratification, and behavioral inhibition. The extended amygdala regulates stress responses and provides balance to the reward system. Healthy neurotransmitter function includes adequate dopamine for motivation and reward, GABA for calming effects, and glutamate for cognitive function, all working in concert to maintain behavioral balance.
What a Healthy State Looks Like:
- Balanced autonomic nervous system function
- Proper neurotransmitter regulation
- Normal stress response patterns
- Healthy sleep-wake cycles
- Stable mood and emotional regulation
- Normal cognitive function and concentration
Understanding the Mechanisms
The biological and neurological factors that contribute to this condition
Pathophysiology
Addiction involves progressive neurobiological changes: (1) Dopamine pathway dysregulation - substances cause dopamine surges 2-10x greater than natural rewards, downregulating D2 receptors and reducing natural reward sensitivity; (2) Prefrontal cortex impairment - chronic use shrinks grey matter, weakening executive function, decision-making, and impulse control; (3) Extended amygdala adaptation - the stress system becomes hyperactive during withdrawal, driving negative reinforcement and compulsive use; (4) Habit formation - use becomes automated through dorsolateral striatum involvement, bypassing conscious decision-making; (5) Memory and conditioning - environmental cues become triggers through amygdala-hippocampus circuitry, causing cravings even after extended abstinence; (6) Glutamaatergic dysfunction - impaired glutamate signaling affects learning, memory, and contributes to relapse vulnerability; (7) Neuroimmune activation - microglial activation and neuroinflammation contribute to craving and compulsive use.
Key Mechanisms:
Addiction involves progressive neurobiological changes: (1) Dopamine pathway dysregulation - substances cause dopamine surges 2-10x greater than natural rewards, downregulating D2 receptors and reducing natural reward sensitivity
(2) Prefrontal cortex impairment - chronic use shrinks grey matter, weakening executive function, decision-making, and impulse control
(3) Extended amygdala adaptation - the stress system becomes hyperactive during withdrawal, driving negative reinforcement and compulsive use
(4) Habit formation - use becomes automated through dorsolateral striatum involvement, bypassing conscious decision-making
(5) Memory and conditioning - environmental cues become triggers through amygdala-hippocampus circuitry, causing cravings even after extended abstinence
(6) Glutamaatergic dysfunction - impaired glutamate signaling affects learning, memory, and contributes to relapse vulnerability
Recognizing the Symptoms
Mental health conditions present with a variety of symptoms affecting different aspects of wellbeing
Important: Everyone experiences mental health differently. If you're experiencing several of these symptoms persistently, we recommend consulting with our mental health specialists.
Commonly Co-Occurring Conditions
Mental health conditions often occur together. Understanding these connections helps provide comprehensive care
Depression
Bidirectional relationship; 30-50% of substance use disorder patients have comorbid depression; self-medication hypothesis; shared neurobiology involving dopamine and serotonin systems
Anxiety Disorders
High comorbidity rates (40-60%); alcohol often used for self-medication; benzodiazepine withdrawal mimics anxiety; shared genetic and environmental risk factors
Post-Traumatic Stress Disorder (PTSD)
Trauma often precedes and maintains addiction; 50% of PTSD patients meet criteria for substance use disorder; self-medication to numb traumatic memories
Chronic Pain
Opioid prescriptions for pain led to epidemic; chronic pain patients develop dependence; bidirectional relationship between pain and substance use
Sleep Disorders
Alcohol disrupts sleep architecture; withdrawal causes insomnia; sleep disturbance increases relapse risk; common in early recovery
Attention Deficit Hyperactivity Disorder (ADHD)
ADHD increases vulnerability to substance use 2-3x; stimulant medications can be misused; dopamine dysregulation common to both conditions
Gastrointestinal Disorders
Alcohol causes gastritis, ulcers, pancreatitis; opioids cause constipation; gut-brain axis involvement in cravings
Liver Disease
Alcoholic hepatitis, cirrhosis; also affects metabolism of substances and medications; contributes to cognitive impairment
Cardiovascular Disease
Stimulant use causes hypertension, arrhythmias; alcohol can cause cardiomyopathy; IV use risk of endocarditis
Our integrated approach addresses all co-occurring conditions simultaneously for comprehensive mental health care.
How We Differentiate
Understanding how this condition differs from similar presentations
| Condition | Overlapping Symptoms | Key Differentiator |
|---|---|---|
| Substance Use Disorder (SUD) | Impaired control, social impairment, risky use, tolerance, withdrawal | DSM-5 criteria require 2+ of 11 criteria within 12-month period; severity graded as mild (2-3), moderate (4-5), or severe (6+) |
| Dependence (Physical) | Tolerance, withdrawal | Physical dependence can occur without addiction (e.g., certain medications); characterized by physiological adaptation, not necessarily compulsive use |
| Abuse (Substance Abuse) | Risky use, failure to fulfill roles | Pre-DSM-5 term; did not include tolerance and withdrawal; replaced by SUD which captures more nuanced presentation |
| Addiction (Behavioral) | Compulsive behaviors, loss of control | Term often used interchangeably with SUD; behavioral addictions (gambling, internet) lack substance involvement but similar neurobiology |
| Relapse | Return to use after abstinence | Part of chronic disease model; not a treatment failure but a temporary setback requiring recommencement of treatment |
| Tolerance | Need for more substance | Physiological adaptation; can develop without dependence or addiction; common with many medications |
| Withdrawal | Physical symptoms upon cessation | Physiological response to cessation; varies by substance; can be medically managed; does not equal addiction |
| Pseudo-addiction | Drug-seeking behavior | Behavior driven by uncontrolled pain, not euphoria; resolves with adequate pain management |
What Causes This Condition?
Multiple factors contribute to mental health conditions. Understanding these helps guide treatment
Genetic Predisposition
60%40-60% - Family history increases risk 2-4x; specific genes affect dopamine signaling (DRD2, DRD4), alcohol metabolism (ADH1B, ALDH2), and reward sensitivity
Family history assessment; genetic testing for risk variants; adoption studies confirm genetic contribution
Early Exposure
30%30% - Adolescent brain particularly vulnerable; early use increases addiction risk 2-3x; prefrontal development disrupted
Age of first use; developmental history; assess brain development impact
Chronic Stress
35%35% - Stress increases substance use motivation; elevates CRF and drives negative reinforcement cycle
Stress history; ACE score; cortisol testing; life events assessment
Trauma
40%40% - Adverse childhood experiences strongly predict addiction; trauma drives self-medication
Trauma history; ACE questionnaire; PTSD screening
Mental Health Conditions
50%50% - Comorbid psychiatric disorders increase addiction risk; self-medication hypothesis
Comprehensive psychiatric evaluation; assess for depression, anxiety, ADHD, PTSD
Social Environment
30%30% - Peer influence; availability; social norms around use; family patterns
Social history; peer network assessment; family history of use
Reward Sensitivity
25%25% - Variable dopamine system sensitivity; high reward sensitivity increases vulnerability
Behavioral assessments; personal history of reward-seeking behaviors
Impaired Executive Function
30%30% - Prefrontal cortex deficits affect impulse control, decision-making
Neuropsychological testing; assess for ADHD; decision-making assessments
Chronic Pain
20%20% - Pain-driven opioid use; pain patients vulnerable to dependence
Pain history; opioid prescription history; alternative pain management assessment
Understanding Your Tests
Key laboratory markers we assess for mental health conditions
| Test | Normal Range | Optimal Range | Unit | Clinical Significance |
|---|---|---|---|---|
| GGT (Gamma-Glutamyl Transferase) | 0-55 U/L | 0-30 U/L | U/L | Liver enzyme elevated with chronic alcohol use; marker of heavy drinking |
| AST/ALT Ratio | 0.5-1.5 | <1.0 | ratio | Ratio >2 suggests alcoholic liver disease; AST typically elevated 2-6x normal in alcohol abuse |
| Mean Corpuscular Volume (MCV) | 80-100 fL | 85-95 fL | fL | Elevated MCV suggests chronic alcohol abuse; macrocytosis from folate deficiency |
| Carbohydrate-Deficient Transferrin (CDT) | <1.7% | <1.2% | % | Specific marker for chronic heavy alcohol consumption; remains elevated 2-4 weeks after cessation |
| Ethyl Glucuronide (EtG) | Negative | Negative | ng/mL | Direct metabolite of ethanol; detects recent alcohol use within 72 hours |
| Phosphatidylethanol (PEth) | <20 ng/mL | 0 ng/mL | ng/mL | Specific alcohol biomarker; elevated levels indicate chronic heavy drinking for 2-4 weeks |
| Urine Drug Screen | Negative | Negative | qualitative | |
| Blood Alcohol Level | 0% | 0% | % | Current intoxication level; legal limit typically 0.08% in most jurisdictions |
| HDL Cholesterol | 40-60 mg/dL | 50-70 mg/dL | mg/dL | Moderate alcohol may raise HDL; very low levels may indicate nutritional deficiency |
| Folate | 3-20 ng/mL | 10-20 ng/mL | ng/mL | Frequent deficiency in alcohol use disorder; contributes to macrocytosis and neurological symptoms |
| Magnesium | 1.5-2.5 mg/dL | 2.0-2.3 mg/dL | mg/dL | Frequently depleted in alcohol use; deficiency contributes to withdrawal symptoms |
| Vitamin B12 | 200-900 pg/mL | 500-800 pg/mL | pg/mL | Often deficient in alcohol abuse; neurological function requires adequate levels |
| TSH | 0.4-4.0 mIU/L | 1.0-2.0 mIU/L | mIU/L | Thyroid dysfunction common in addiction; hyper/hypothyroidism can mimic anxiety |
| Cortisol (AM) | 5-25 mcg/dL | 8-14 mcg/dL | mcg/dL | HPA axis dysregulation common; chronic stress and withdrawal affect levels |
| HbA1c | <5.7% | <5.5% | % | Alcohol can affect blood sugar; some substances cause metabolic changes |
| HIV/Hepatitis Panel | Negative | Negative | qualitative | IV drug use increases transmission risk; routine screening recommended |
Why Treatment Matters
Untreated mental health conditions can worsen over time and impact all areas of life
Physical Health Deterioration
Organ damage (liver, heart, brain); increased infection risk; neurological damage; cancer risk; premature death (average lifespan reduction 10-20 years)
Mental Health worsening
Comorbid depression and anxiety worsen; increased suicide risk (10-20x higher); cognitive decline; emotional numbing
Relationships and Family Destruction
Broken marriages; estrangement from children; lost friendships; family trauma passed to next generation
Occupational and Financial Collapse
Job loss; bankruptcy; legal problems; homelessness; inability to maintain basic responsibilities
Legal Consequences
DUI arrests; drug possession charges; incarceration; criminal record affecting employment
Overdose and Death
Opioid overdoses killed 80,000+ in US in 2021; Fentanyl contamination increasingly common; risk highest during relapse after tolerance reduction
Secondary Health Conditions
HIV/Hepatitis from IV use; TB; pneumonia; cardiovascular disease; cancers linked to substance use
Quality of Life Annihilation
Complete loss of meaningful life; isolation; shame; hopelessness; existential suffering
How We Diagnose
Comprehensive diagnostic testing to understand your unique condition
Comprehensive Addiction Assessment
Purpose: Establish diagnosis and severity
DSM-5 criteria fulfillment; substance use history; consequences; readiness to change
Urine Drug Screen
Purpose: Detect recent substance use
Opioids, amphetamines, cocaine, benzodiazepines, cannabis, barbiturates, metabolites
Blood Alcohol Level / Breathalyzer
Purpose: Assess current intoxication
Blood alcohol concentration; recent use
Liver Function Tests
Purpose: Assess alcohol impact on liver
GGT, AST, ALT, bilirubin; markers of alcoholic hepatitis, cirrhosis
Complete Blood Count
Purpose: Assess overall health
MCV (macrocytosis), anemia, infection, immune function
Comprehensive Metabolic Panel
Purpose: Assess organ function and electrolytes
Kidney function, electrolytes, blood sugar, liver function
Lipid Panel
Purpose: Assess cardiovascular risk
Cholesterol, triglycerides; alcohol affects lipid metabolism
Infectious Disease Screening
Purpose: Screen for bloodborne pathogens
HIV, Hepatitis B and C
Nutritional Assessment
Purpose: Identify deficiencies
Vitamin B12, folate, magnesium, iron studies
Cardiac Biomarkers
Purpose: Assess cardiovascular impact
For stimulant and alcohol use; troponin, ECG if indicated
Psychiatric Evaluation
Purpose: Assess co-occurring disorders
Depression, anxiety, PTSD, ADHD screening; severity ratings
Neuropsychological Testing
Purpose: Assess cognitive function
Executive function, memory, attention; frontal lobe assessment
All diagnostic tests are conducted in our state-of-the-art facility with quick turnaround times.
Our Approach to Treatment
A phased approach addressing symptoms and root causes for lasting recovery
Phase 1: Assessment and Stabilization
Comprehensive evaluation and medical stabilization
Interventions:
- Complete addiction assessment using DSM-5 criteria
- Medical evaluation and laboratory testing
- Psychiatric evaluation for co-occurring disorders
- Safe detoxification if medically indicated
- Medication-assisted treatment initiation if appropriate
- Motivational interviewing to enhance readiness
- Establish therapeutic alliance
- Assess social support and resources
Phase 2: Detoxification and Early Abstinence
Medical stabilization and withdrawal management
Interventions:
- Medically supervised detoxification
- Medication management (naltrexone
- acamprosate
- buprenorphine as indicated)
- 24/7 support access
- Early relapse prevention skills
- Address acute cravings
- Sleep optimization
- Nutritional rehabilitation
- Begin 12-step or alternative support group integration
Phase 3: Intensive Recovery
Address underlying issues and build recovery skills
Interventions:
- Individual therapy (CBT
- DBT
- trauma-focused)
- Group therapy and process groups
- Family therapy and education
- Cognitive remediation if needed
- Address co-occurring mental health conditions
- Develop coping strategies for triggers and cravings
- Build sober social support network
- Life skills training
- Medication management and adjustment
Phase 4: Early Maintenance
Consolidate gains and prevent relapse
Interventions:
- Continue therapy (reduced frequency)
- Relapse prevention planning
- Sober living transition if needed
- Vocational/educational support
- Family reconciliation work
- Mindfulness and stress management
- Exercise and wellness programming
- Ongoing medication management
Phase 5: Long-Term Recovery
Maintain sobriety and optimize quality of life
Interventions:
- Maintenance therapy
- Ongoing support group participation
- Lifestyle restructuring
- Meaningful activities and purpose development
- Relationship repair and building
- Career and life goals pursuit
- Continued monitoring and early intervention
- Annual reassessment
Phase 6: Sustained Recovery
Prevent relapse and thrive
Interventions:
- Maintenance and monitoring
- Peer support and sponsorship
- Giving back (service)
- Relapse prevention refresher
- Ongoing wellness
- Legacy building
Supporting Your Recovery
Evidence-based lifestyle modifications that support mental health treatment
No items available for this category
Measuring Progress
Key indicators we track to ensure you're on the right path to recovery
We regularly assess these metrics and adjust your treatment plan accordingly
Common Questions Answered
Author Credentials
Dr. Hafeel Ambalath - DHA Licensed Integrative and Functional Medicine Physician with specialized training in addiction medicine, co-occurring disorders, and the neurobiology of recovery. Expert in treating substance use disorders using comprehensive functional medicine approaches combined with evidence-based behavioral therapies and medication-assisted treatment.
References & Sources
- Volkow ND, Koob GF, McLellan AT. Neurobiologic advances from the brain disease model of addiction. N Engl J Med. 2016.
- Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2016.
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Ed. DSM-5. 2013.
- National Institute on Drug Abuse. Principles of Drug Addiction Treatment: A Research-Based Guide. NIH Publication No. 19-DA-5601. 2019.
- Substance Abuse and Mental Health Services Administration. Treatment Improvement Protocol (TIP) Series. HHS Publication No. (SMA) 19-4523.
- Kleber HD, Weiss RD, Anton RF Jr, et al. Practice guideline for the treatment of patients with substance use disorders. Am J Psychiatry. 2006.
- Miller WR, Rollnick S. Motivational Interviewing: Helping People Change. 3rd ed. Guilford Press. 2012.
- Koob GF. The dark side of emotion: The addiction perspective. Eur J Pharmacol. 2015.
- Volkow ND, Wang GJ, Fowler JS, et al. Addiction: beyond dopamine reward circuitry. Proc Natl Acad Sci U S A. 2001.
- Weiss RD, Griffin ML, Greenfield SF, et al. Group therapy for patients with substance use disorders. Focus. 2019.
- Stahl SM. Essential Psychopharmacology: The Prescriber's Guide. Cambridge University Press. 2021.
- World Health Organization. Atlas on Substance Use Disorders. Geneva: WHO. 2010.
Ready to Start Your Recovery Journey?
Our experienced mental health specialists are ready to help you overcome this condition with personalized, evidence-based treatment.
Your first consultation includes a comprehensive assessment at no additional cost